ABSTRACT
INTRODUCTION
Chronic, hard-to-heal wounds include venous leg ulcers, diabetic foot ulcers, and decubitus (pressure) ulcers. Although the pathogenesis of these wounds is not well understood, they have been associated with microvascular, macrovascular, or neurologic insufficiency. In the United States, there are more than 3 million chronic wound patients (5, 10, 18, 21) .
Treatment of chronic wounds such as venous leg ulcers has relied on the use of dressings to provide protection from infection and further injury, to control exudate, and to promote closure. Wound-healing products based on cytokines or growth factors, e.g., platelet-derived growth factor-(3, basic fibroblast growth factor, transforming growth factor-P, and granulocyte-macrophage colonystimulating factor, are presently available or under investigation (2, 3, 7, 16 (6, 9, 20) . These results are in agreement with published data indicating that cultured keratinocytes and fibroblasts are of low antigenicity and immunogenicity (11, 19 (8, 12) . In these animals, Apligraf lig cells were detected for up to 60 days. The persistence of Apligraf ĩ n patients is under investigation (6, 17 (4, 6) .
